Research use only. All compounds are for laboratory research. Not for human or veterinary use. 21+.

CJC-1295 No DAC: What the Research Shows

CJC-1295 No DAC, also called Modified GRF 1-29 (Mod GRF 1-29), is a synthetic analog of the first 29 amino acids of growth-hormone-releasing hormone (GHRH 1-29). It carries four amino-acid substitutions that improve stability relative to native GHRH but, unlike the DAC-bearing version, does not include the Drug Affinity Complex. Without DAC, the compound does not bind circulating albumin, giving it a short half-life and producing discrete growth-hormone pulses rather than sustained elevation in research models.

This pharmacokinetic profile makes CJC-1295 No DAC a preferred tool compound when researchers need to study pulsatile GH-secretion patterns that more closely mirror endogenous GH-release dynamics. It is supplied as a lyophilized powder and is water-soluble on reconstitution.

Verified compound data

Property Value
Compound name CJC-1295 No DAC (Modified GRF 1-29 / Mod GRF 1-29)
CAS number 863288-34-0
PubChem CID 56841945 (also indexed as 91976842)
Molecular formula C152H252N44O42
Molecular weight ~3367.9 g/mol
Sequence H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
Length 29 residues, C-terminal amide
Physical form Lyophilized powder

Data verified against PubChem (CID 56841945) and supplier COA / Peptpedia. The CJC-1295 with DAC variant is a different compound: PubChem CID 91971820, C165H269N47O46.

Research-context mechanism

In preclinical literature, CJC-1295 No DAC is associated with agonism at the GHRH receptor on pituitary somatotrophs. Research suggests it activates GHRH-receptor signaling to drive growth-hormone release; without albumin binding, this produces short, discrete GH pulses in animal models. Comparative pharmacokinetic studies examine it against the DAC-bearing version, which exhibits a markedly longer half-life. These mechanisms are described strictly in preclinical / animal research contexts and are not established human-use mechanisms.

Current research summary

CJC-1295 No DAC appears in GH-axis pharmacology literature, typically in:

  • Pulsatile GH-secretion studies via GHRH-receptor activation
  • Comparative pharmacokinetics versus CJC-1295 with DAC
  • GH-axis signaling in animal models
  • Synergistic secretagogue studies (commonly paired with a ghrelin-receptor agonist such as ipamorelin)

It is frequently used alongside ipamorelin in research examining combined GHRH-analog plus GH-secretagogue signaling. CJC-1295 No DAC is not an FDA-approved drug and has no established human therapeutic use.

Frequently Asked Questions

What is CJC-1295 No DAC?

CJC-1295 No DAC (Modified GRF 1-29) is a synthetic 29-residue analog of GHRH 1-29 without the Drug Affinity Complex. In research models it produces short, pulsatile growth-hormone release. It is a research compound, not for human use.

What is the difference between CJC-1295 with DAC and without DAC?

The DAC (Drug Affinity Complex) lets the peptide bind circulating albumin, extending its half-life to days. Without DAC, CJC-1295 has a short half-life and produces discrete GH pulses. They are chemically distinct: No DAC is C152H252N44O42; with DAC is C165H269N47O46.

What is the molecular formula of CJC-1295 No DAC?

The molecular formula is C152H252N44O42, with a molecular weight of approximately 3367.9 g/mol (PubChem CID 56841945).

What is the CAS number for CJC-1295 No DAC?

The CAS registry number for CJC-1295 No DAC (Modified GRF 1-29) is 863288-34-0.

What is the sequence of CJC-1295 No DAC?

The 29-residue sequence is H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, a Modified GRF 1-29 analog with a C-terminal amide.

Is CJC-1295 No DAC approved for human use?

No. CJC-1295 No DAC is not an FDA-approved drug and is not intended for human consumption. It is offered strictly as a research compound for laboratory use.

For research use only. Not for human or veterinary use. Not approved by the FDA. 21+

All compounds described in Vantage Aminos research content are sold for laboratory and scientific research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition. For research use only.
  • HPLC + MS tested, every batch
  • U.S. synthesized
  • Batch COA on the product page